NASDAQ · IBIO
Healthcare · Biotechnology
$0.77
Down-$0.04 (-5.52%)
Updated Nov 2, 2026, 9:05 AM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · IBIO
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
IBIO closed at $0.77 after 20 trading sessions, down 31.37% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $0.81 | $0.8106 | $0.74 | $0.7687 | 214.29K |
| Oct 29, 2026 | $0.819 | $0.83 | $0.7768 | $0.8136 | 248.63K |
| Oct 28, 2026 | $0.77 | $0.808 | $0.7401 | $0.8042 | 281.72K |
| Oct 27, 2026 | $0.7071 | $0.7739 | $0.69 | $0.7669 | 478.17K |
| Oct 26, 2026 | $0.73 | $0.73 | $0.6859 | $0.707 | 509.28K |
| Oct 23, 2026 | $0.77 | $0.784 | $0.7109 | $0.7178 | 655.17K |
| Oct 22, 2026 | $0.84 | $0.8496 | $0.75 | $0.784 | 654.79K |
| Oct 21, 2026 | $0.843 | $0.8798 | $0.84 | $0.84 | 518.04K |
| Oct 20, 2026 | $0.7601 | $0.8914 | $0.7601 | $0.821 | 2.22M |
| Oct 19, 2026 | $0.759 | $0.7776 | $0.75 | $0.7601 | 355.6K |
| Oct 16, 2026 | $0.784 | $0.7999 | $0.7601 | $0.7663 | 312.7K |
| Oct 15, 2026 | $0.75 | $0.8208 | $0.75 | $0.7828 | 354.73K |
| Oct 14, 2026 | $0.7754 | $0.81 | $0.7328 | $0.7808 | 1.44M |
| Oct 13, 2026 | $0.8977 | $0.8977 | $0.77 | $0.7818 | 1.35M |
| Oct 12, 2026 | $0.89 | $0.95 | $0.8849 | $0.9032 | 452.15K |
| Oct 9, 2026 | $0.92 | $0.9698 | $0.8506 | $0.871 | 1.65M |
| Oct 8, 2026 | $1.00 | $1.0001 | $0.9002 | $0.92 | 685.12K |
| Oct 7, 2026 | $1.05 | $1.06 | $0.97 | $1.01 | 2.71M |
| Oct 6, 2026 | $1.12 | $1.15 | $1.02 | $1.05 | 1.21M |
| Oct 5, 2026 | $1.14 | $1.18 | $1.08 | $1.12 | 1.13M |
The latest Smart Investors Daily articles mentioning IBIO.
Company
Market Activity
Research & News
IBIO research
Company profile and research snapshot.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 17, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 2, 2026 | Chardan Capital | Buy | — |
| Jun 8, 2026 | Raymond James | Outperform | — |
| Apr 9, 2026 | Chardan Capital | Buy | — |
| Mar 18, 2026 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 29, 2026
There are parts of the stock market where I am comfortable doing the research myself.Give me a community bank’s balance sheet, loan portfolio, and deposit information, and I can usually figure out whether the shares
Yahoo · Oct 13, 2026
In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone iBio expects to start first-in-human trials of IBIO-610 in first half of 2027 SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, highlighted preclinical body-composition data f
Benzinga · Oct 13, 2026
In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide aloneiBio expects to start first-in-human trials of IBIO-610 in
SeekingAlpha · Oct 7, 2026
2026-10-07. The following slide deck was published by iBio, Inc.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IBIO.
